Royalty Pharma

Royalty Pharma is a global leader in the biopharmaceutical royalty market, specializing in funding life sciences innovation. They are the largest buyer of biopharmaceutical royalties, with a portfolio that encompasses more than 35 commercial products and 16 development-stage product candidates. Royalty Pharma partners with innovators, ranging from academic institutions and non-profits to small and mid-cap biotechnology companies and large pharmaceutical companies, providing tailored funding solutions to help them reach their goals.

Their unique business model involves acquiring royalties on existing or new therapies, providing funding for research and development, and facilitating mergers and acquisitions. Royalty Pharma's expertise in science, medicine, and investing enables them to identify promising opportunities and support the advancement of life-saving therapies. They also prioritize responsible investing, aligning with the UN Sustainable Development Goals and promoting access to healthcare through their partnerships.

Royalty Pharma offers a comprehensive benefits package designed to support employee well-being and professional growth. These benefits include employee wellness initiatives, various professional development training opportunities, including a six-month leadership program and an advanced negotiation course, and an open-door culture that encourages open communication and feedback. The company also actively promotes diversity, equity, and inclusion through a dedicated taskforce that works to embed DEI principles into all aspects of the workplace culture.

Royalty Pharma is the world's largest buyer of biopharmaceutical royalties, dedicated to funding innovation across the life sciences ecosystem. They partner with a wide range of organizations, from academic institutions and non-profits to small and large biopharmaceutical companies, providing capital in exchange for existing or newly-created royalties on approved products or development-stage therapies. This unique business model allows Royalty Pharma to accelerate the development and commercialization of life-saving therapies, while simultaneously generating attractive returns for their investors and enabling their partners to achieve their goals.

Royalty Pharma cultivates a collaborative and inclusive culture that values teamwork, critical thinking, innovation, and the pursuit of excellence. They foster an environment where diverse skills and backgrounds are valued, encouraging debate and challenging assumptions to achieve better outcomes. Their team-oriented approach promotes long-term employee retention and an owner-operator mindset, with employees owning one-third of the company's shares. This shared stake in the company's success drives a culture of engaged, diverse, and high-performing teams.

Royalty Pharma is committed to promoting diversity, equity, and inclusion (DEI) in the workplace. The company has established a DEI taskforce comprised of a cross-section of employees who share DEI efforts internally and provide suggestions and recommendations for integrating DEI into all aspects of the company culture. Royalty Pharma aims to create an environment where employees feel empowered to bring their full and authentic selves to work, valuing diversity of experience, perspective, and background.